Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$113.10 USD

113.10
2,705,382

+0.40 (0.36%)

Updated Aug 27, 2024 04:00 PM ET

Pre-Market: $113.00 -0.10 (-0.09%) 9:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

DexCom Stock May Gain on Expanded Reach After Stelo's US Launch

DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.

Abbott's Core Businesses Thrive Despite Macroeconomic Issues

ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.

The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace

Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Eli Lilly, Chevron & Abbott

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Chevron Corporation (CVX) and Abbott Laboratories (ABT), as well as a micro-cap stocks Bridger Aerospace Group Holdings, Inc. (BAER).

Why Is Boston Scientific (BSX) Up 7.2% Since Last Earnings Report?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen

Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.

Abbott (ABT) Advances While Market Declines: Some Information for Investors

Abbott (ABT) closed the most recent trading day at $112.10, moving +0.64% from the previous trading session.

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Urmimala Biswas headshot

Should You Buy, Sell or Hold Medtronic (MDT) Before Q1 Earnings?

Medtronic's (MDT) first-quarter profits might have been dented by higher costs and expenses originating from macro issues and geopolitical complexities. However, innovations may have boosted the top line.

Medtronic (MDT) Progresses in CGM With New Approval, Alliance

The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.

Urmimala Biswas headshot

Abbott Up 7.7% Post Q2 Earnings: Should You Buy ABT Stock?

Abbott's (ABT) strong growth projection for 2024 is an indication that the stock will be able to sustain the positive momentum through the rest of the year.

OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down

Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.

Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall

Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.

Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up

Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.

National Vision (EYE) Tops Q2 Earnings, Lowers '24 Outlook

National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.

Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised

Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.

Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down

Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.

Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View

Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.

STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls

STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.

Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up

Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.

CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook

CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.

Is Trending Stock Abbott Laboratories (ABT) a Buy Now?

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised

Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.

IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down

IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.